Interius BioTherapeutics Raises $76M in Series A Financing
Summary
Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing. All existing investors participated, including lead founding investor Tellus BioVentures, the University of Pennsylvania and Penn Medicine, Agent Capital, the Mark Foundation for Cancer Research, Knollwood, and BrightEdge, the American Cancer Society’s impact investment fund. Co-founded by Dr. Saar Gill, physician-scientist at the University of Pennsylvania, and Bruce Peacock, a renowned biotech veteran, and led by Phil Johnson, MD, CEO, Interius is initially focused on treating hematologic malignancies by leveraging its novel gene delivery platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. This therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments. Exploiting its versatile platform, Interius is also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.
Funding
Review available funding amount, funding date, investors, and linked company information related to Interius BioTherapeutics Raises $76M in Series A Financing in the interactive ISVWorld profile.